$BSX (BOSTON SCIENTIFIC) — 8-K: Boston Scientific names Joseph M. Fitzgerald COO, creates three reportable segments effective Jan. 1, 2027

Joseph M. Fitzgerald, currently executive vice president and group president, Cardiovascular, becomes executive vice president and chief operating officer effective Jan. 1, 2027, overseeing global operations, business units and regions. Boston Scientific will establish three reportable segments effective Jan. 1: Interventional Therapies, Rhythm Solutions and MedSurg. Lance Bates will lead Interventional Therapies, Nick Spadea-Anello will lead Rhythm Solutions, and Stephen Morse will serve as executive vice president and president, MedSurg and Asia Pacific; each reports to Fitzgerald. The structure is designed to enable faster decision making and support strategic allocation of investments.

Joseph M. Fitzgerald, currently executive vice president and group president, Cardiovascular, becomes executive vice president and chief operating officer effective Jan. 1, 2027, overseeing global ope